Business Context and Reporting Period
This Form 8-K Current Report was filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on June 27, 2018. The registrant is a Delaware corporation headquartered in Boston, Massachusetts, and is classified as an emerging growth company. The report details the entry into a material definitive agreement regarding a public equity offering.
Key Financial Metrics and Transaction Details
- Transaction Type: Public offering of common stock.
- Shares Offered: 8,000,000 shares of common stock ($0.001 par value).
- Offering Price: $7.50 per share.
- Net Proceeds: Approximately $56.4 million (after underwriting discounts and commissions, before offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 1,200,000 shares.
- Expected Closing Date: July 2, 2018.
- Underwriters: Cowen and Company, LLC and Piper Jaffray & Co.
Note: This filing does not provide revenue, profit, cash flow, margin, or debt metrics for the company's operations.
Material Changes
The primary material change reported is the execution of an Underwriting Agreement to raise capital through the sale of new equity. This represents a significant increase in the company's share count and cash liquidity upon closing, subject to customary conditions.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, operational outlook, or management commentary regarding future performance beyond the transaction details. The transaction is subject to the satisfaction of customary closing conditions. The filing references press releases issued on June 27 and June 28, 2018, for further details on the offering announcement and pricing.
Investor Verification Checklist
- Verify the final closing date of the offering (expected July 2, 2018) and confirm if the over-allotment option was exercised.
- Review the final prospectus supplement to confirm the exact net proceeds after deducting all offering expenses.
- Check subsequent filings for the updated share count and diluted ownership structure post-offering.
- Confirm the intended use of the $56.4 million in net proceeds as disclosed in the prospectus.